Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO)

Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO)

Abstract Background Sotrovimab, a monoclonal antibody with efficacy against SARS-CoV-2 including certain Omicron variants, has been used in treatment of mild-moderate COVID-19. Limited data exists regarding its use in pregnant women. Methods Electronic medical record review of pregnant COVID-19 pati...

Full description

Bibliographic Details
Main Authors: Jessica J. Tuan, Manas Sharma, Jehanzeb Kayani, Matthew W. Davis, Dayna McManus, Jeffrey E. Topal, Onyema Ogbuagu
Format: Article
Language:English
Published: BMC 2023-04-01
Series:BMC Infectious Diseases
Subjects:
Sotrovimab
COVID-19
Omicron
Pregnancy
Monoclonal antibodies
Online Access:https://doi.org/10.1186/s12879-023-08198-9

Internet

https://doi.org/10.1186/s12879-023-08198-9

Similar Items